Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 192

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 192
---
145,224)Other comprehensive income— — — 7,529 — 7,529 Balance at December 31, 2023138,385,498 $1,711 $2,144,811 $643 $(1,116,211)$1,030,954 Issuance of common stock and pre-funded warrants, net of issuance costs of $4803,244,689 32 499,221 — — 499,253 Issuances under equity incentive plans1,288,609 13 17,376 — — 17,389 Vesting of restricted stock units1,302,190 12 (12)— — — Stock-based compensation— — 103,484 — — 103,484 Net loss— — — — (422,773)(422,773)Other comprehensive income— — — 1,377 — 1,377 Balance at December 31, 2024144,220,986 $1,768 $2,764,880 $2,020 $(1,538,984)$1,229,684 

See accompanying notes to consolidated financial statements.

139

Denali Therapeutics Inc.

Consolidated Statements of Cash Flows

(In thousands)

Year Ended December 31,202420232022Operating activitiesNet loss$(422,773)$(145,224)$(325,991)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization7,795 16,726 10,383 Stock-based compensation expense102,878 108,102 99,847 Net accretion of discounts on marketable securities(35,117)(43,952)(1,637)Non-cash adjustment to operating lease expense(4,074)(3,719)(3,351)Right-of-use asset amortization for finance lease1,197 — — Non-cash gain from divestiture of small molecule programs(14,537)— — Other non-cash items— 2 63 Changes in operating assets and liabilities:Prepaid expenses and other assets(2,480)(4,094)(2,760)Other non-current assets603 — — Accounts payable1,437 2,431 2,274 Accruals and other current liabilities17